Ruling or order TX

Eli Lilly, Novo Nordisk Antitrust Suit Remains Dismissed

Ruling or order from the legal press · reported by 3 publishers

Headline as published by Law360 Texas on Oct 23, 2026; collected by the wire Oct 23, 2026, 10:15 PM ET.

Read at Law360 Texas

Coverage

  1. Law360 Texas Legal press

    Eli Lilly, Novo Nordisk Antitrust Suit Remains Dismissed

  2. Law360 Life Sciences Legal press

    Eli Lilly, Novo Nordisk Antitrust Suit Remains Dismissed

  3. Law360 Health Legal press

    Eli Lilly, Novo Nordisk Antitrust Suit Remains Dismissed

Named in this story

Topics

Explore the named firms, organizations and MDL dockets above. Sources and method

MDL No. 3094

GLP-1 Receptor Agonists

IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation

Transferee judge
Karen S. Marston
Court
Eastern District of Pennsylvania
Actions pending
4,025

Per the JPML pending-dockets report of October 1, 2026.